Feeds:
Posts
Comments

Search Results for 'Pfizer'


First single-course ‘curative’ CRISPR Shot by Intellia rivals Alnylam, Ionis and Pfizer Reporter: Aviva Lev-Ari, PhD, RN   Intellia to kick-start first single-course ‘curative’ CRISPR shot, as it hopes to beat rivals Alnylam, Ionis and Pfizer by Ben Adams | Oct 19, 2020 10:39am It’s been a good year for Intellia: One of its founders, Jennifer Doudna, […]

Read Full Post »


The complication of Pfizer’s Vaccine Distribution’s Plan Reporter : Irina Robu, PhD Even though Pfizer announcing the development of safe and effective vaccine is cause for celebration, scientists and public experts face  the challenge of how to quickly make millions of doses of the vaccine and getting them to hospitals, clinics and pharmacies. But Pfizer […]

Read Full Post »


Pfizer buys out Array BioPharma for $11.4 Billion to beef up its oncology offerings Reporter: Stephen J. Williams, PhD As reported in FiercePharma.com: by Angus Liu | Jun 17, 2019 11:42am Three years after purchasing Medivation for $14.3 billion, Pfizer is back with another hefty M&A deal. And once again, it’s betting on oncology. In the first […]

Read Full Post »


Third Boston Pharmaceutical Symposium on May 3, 2019 at Pfizer, Building 2, Kendall Sq., Cambridge MA Reporter: Aviva Lev-Ari, PhD, RN   The Boston Chapter of the American Statistical Association (BCASA) invites you all to attend the Third Boston Pharmaceutical Symposium on May 3, 2019 at Pfizer, Building 2, Kendall Sq., Cambridge MA.   As […]

Read Full Post »


From Thalidomide to Revlimid: Celgene to Bristol Myers to possibly Pfizer; A Curation of Deals, Discovery and the State of Pharma   Curator: Stephen J. Williams, Ph.D. Updated 6/24/2019 Updated 4/12/2019 Updated 2/28/2019 Lenalidomide (brand name Revlimid) is an approved chemotherapeutic used to treat multiple myeloma, mantle cell lymphoma, and certain myedysplastic syndromes.  It is […]

Read Full Post »


Tweets for AI and Machine Learning in Clinical Trials April 12th, 2018 hosted at Pfizer’s Innovation Research Lab in Cambridge, MA @AVIVA1950 @pharma_BI     Aviva Lev-Ari‏ @AVIVA1950 40s41 seconds ago More Aviva Lev-Ari‏ @AVIVA1950 2m2 minutes ago More Aviva Lev-Ari‏ @AVIVA1950 2m2 minutes ago More Aviva Lev-Ari‏ @AVIVA1950 3m3 minutes ago More Aviva Lev-Ari‏ @AVIVA1950 3m3 minutes ago More Aviva Lev-Ari‏ @AVIVA1950 3m3 minutes ago More […]

Read Full Post »


Synopsis for AI & Machine Learning in Clinical Trials, APRIL 12, 2018 PFIZER INNOVATION RESEARCH LAB – CAMBRIDGE, MA   Recap Book http://viewer.zmags.com/publication/9d58c338#/9d58c338/30   Aviva Lev-Ari, PhD, RN, Director and Founder of  LPBI Group,  will attend and cover in Real Time the Conference  @pharma_BI @AVIVA1950 Tweets for AI and Machine Learning in Clinical Trials April 12th, […]

Read Full Post »


More Awards to Jennifer Doudna: 2016 Warren Alpert Foundation Prize and The 2015 Pfizer Lecture Reporter: Aviva Lev-Ari, PhD, RN   2015 Inaugural Pfizer Lecture with Jennifer Doudna, Ph.D. Pfizer Cambridge presents the 2015 Inaugural Pfizer Lecture honoring Jennifer Doudna, Ph.D., innovator in the field of biomedical research, on Thursday, Sept. 10, 2015 September 10, […]

Read Full Post »


  SAN DIEGO, CA – December 8, 2015 – BioAtla® LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. (NYSE: PFE) to advance the development and commercialization of a new class of antibody therapeutics based on […]

Read Full Post »


Allergan, Pfizer Deal Goes Through with Allergan Bigger Than Pfizer: But at What Cost to R&D? Curator: Stephen J. Williams, Ph.D. Just recently this site had a post entitled Pfizer Near Allergan Buyout Deal But Will Fed Allow It?  Now, as Bloomberg reports the international deal between Allergan and Pfizer has gone through, resulting in a […]

Read Full Post »

Next »